CN104717966B - 用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物 - Google Patents

用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物 Download PDF

Info

Publication number
CN104717966B
CN104717966B CN201380053346.1A CN201380053346A CN104717966B CN 104717966 B CN104717966 B CN 104717966B CN 201380053346 A CN201380053346 A CN 201380053346A CN 104717966 B CN104717966 B CN 104717966B
Authority
CN
China
Prior art keywords
hemoglobin
tumor
cells
cancer
based oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380053346.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104717966A (zh
Inventor
黄炳镠
卫凤文
郭瑞仪
刘思行
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VISION GLOBAL HOLDINGS Ltd
Original Assignee
VISION GLOBAL HOLDINGS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VISION GLOBAL HOLDINGS Ltd filed Critical VISION GLOBAL HOLDINGS Ltd
Publication of CN104717966A publication Critical patent/CN104717966A/zh
Application granted granted Critical
Publication of CN104717966B publication Critical patent/CN104717966B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380053346.1A 2012-10-12 2013-10-11 用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物 Expired - Fee Related CN104717966B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261712853P 2012-10-12 2012-10-12
US61/712,853 2012-10-12
US13/713,031 2012-12-13
US13/713,031 US20140106004A1 (en) 2012-10-12 2012-12-13 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
PCT/US2013/064418 WO2014059199A1 (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Publications (2)

Publication Number Publication Date
CN104717966A CN104717966A (zh) 2015-06-17
CN104717966B true CN104717966B (zh) 2018-08-24

Family

ID=50475529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380053346.1A Expired - Fee Related CN104717966B (zh) 2012-10-12 2013-10-11 用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物

Country Status (21)

Country Link
US (2) US20140106004A1 (https=)
EP (1) EP2906222A4 (https=)
JP (1) JP6113850B2 (https=)
KR (1) KR20150065881A (https=)
CN (1) CN104717966B (https=)
AP (1) AP2015008315A0 (https=)
AR (1) AR093023A1 (https=)
AU (1) AU2013329121B2 (https=)
BR (1) BR112015007475A2 (https=)
CA (1) CA2884521C (https=)
CL (1) CL2015000897A1 (https=)
EA (1) EA201500301A1 (https=)
IL (1) IL237763A (https=)
MA (1) MA37994A2 (https=)
MX (1) MX367562B (https=)
PH (1) PH12015500562B1 (https=)
SG (3) SG10201608747RA (https=)
TW (1) TW201414489A (https=)
UY (1) UY35082A (https=)
WO (1) WO2014059199A1 (https=)
ZA (1) ZA201501949B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) * 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
KR102854338B1 (ko) 2017-06-26 2025-09-03 루넬라 바이오테크 인코포레이티드 미토케토신: 암 세포에서 케톤 대사를 표적화하는 미토콘드리아-기반의 치료제
JPWO2019124423A1 (ja) * 2017-12-19 2020-10-22 国立大学法人 岡山大学 がんの進行抑制、治療、予防及び／又は再発予防剤
CN111558032B (zh) * 2020-05-19 2023-08-22 中国科学院宁波材料技术与工程研究所 一种蛋白纳米药物及其制备方法与应用
CN114344263B (zh) * 2022-02-21 2023-08-01 杭州普略生物科技有限公司 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用
KR102793996B1 (ko) 2022-03-31 2025-04-09 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물
WO2025222059A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Method of treating cancer using pegylated bovine hemoglobin
CN119746044A (zh) * 2025-03-06 2025-04-04 润方（北京）生物医药研究院有限公司 血红蛋白氧载体在制备抗病毒药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405051A (zh) * 2010-05-27 2012-04-04 黄炳镠 一种制备高温稳定的包含氧载体的药物组合物的方法及其应用
CN102510753A (zh) * 2010-06-23 2012-06-20 黄炳镠 一种制备热稳定的包含氧载体的组合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP2006508939A (ja) * 2002-10-29 2006-03-16 エンジーン， インコーポレイテッド 癌処置のための組成物
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
NO2440239T3 (https=) * 2009-06-09 2018-02-10
EP2451459B1 (en) * 2009-07-07 2017-11-22 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405051A (zh) * 2010-05-27 2012-04-04 黄炳镠 一种制备高温稳定的包含氧载体的药物组合物的方法及其应用
CN102510753A (zh) * 2010-06-23 2012-06-20 黄炳镠 一种制备热稳定的包含氧载体的组合物的方法

Also Published As

Publication number Publication date
JP2015534946A (ja) 2015-12-07
AU2013329121A1 (en) 2015-04-09
PH12015500562A1 (en) 2015-05-04
US9056098B2 (en) 2015-06-16
ZA201501949B (en) 2016-01-27
SG11201502133SA (en) 2015-04-29
BR112015007475A2 (pt) 2017-08-08
US20140106004A1 (en) 2014-04-17
SG10201608747RA (en) 2016-12-29
JP6113850B2 (ja) 2017-04-12
WO2014059199A8 (en) 2014-05-30
IL237763A (en) 2017-07-31
CN104717966A (zh) 2015-06-17
CA2884521C (en) 2018-05-01
MX2015004512A (es) 2015-12-01
EA201500301A1 (ru) 2015-08-31
EP2906222A4 (en) 2016-06-22
MX367562B (es) 2019-08-27
PH12015500562B1 (en) 2015-05-04
TW201414489A (zh) 2014-04-16
HK1206281A1 (en) 2016-01-08
EP2906222A1 (en) 2015-08-19
SG10201607846PA (en) 2016-11-29
CA2884521A1 (en) 2014-04-17
US20140303085A1 (en) 2014-10-09
CL2015000897A1 (es) 2015-08-21
UY35082A (es) 2014-07-31
MA37994A2 (fr) 2016-06-30
AR093023A1 (es) 2015-05-13
AU2013329121B2 (en) 2017-05-25
AP2015008315A0 (en) 2015-03-31
KR20150065881A (ko) 2015-06-15
WO2014059199A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CN104717966B (zh) 用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物
Lee et al. Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction
CN111787945B (zh) 作为癌症免疫治疗的检查点阻断剂的工程化纳米囊泡
Yin et al. Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways
Luo et al. Perfluorotributylamine-loaded albumin nanoparticles downregulate platelet-derived TGFβ to inhibit tumor metastasis
ES2913073T3 (es) Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis
CN106565825A (zh) 稳定化a7r多肽及其在构建肿瘤靶向诊治递药系统中的用途
JP6100252B2 (ja) 異なる治療用途のための熱安定性酸素キャリアを含有する医薬組成物
Ruoslahti Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier
JPWO2018021200A1 (ja) Ｒｕｎｘ阻害剤
Shimizu et al. Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors
Qin et al. Hybrid cell membranes camouflaged copper-loaded nano-prodrug for tumor angiogenesis inhibition and cell cuproptosis
CN102573853A (zh) 使用肌醇三焦磷酸减少多药抗性的方法
Luo et al. Genetically engineered biomimetic nanoparticles for synergistic activation of glioma-associated macrophages against glioblastoma
JP2018035112A (ja) 抗癌剤の抗腫瘍効果の増強剤、癌治療剤、及び癌治療用医薬組成物。
US20200155594A1 (en) Hornerin: a novel non-vegf mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells
Zhang et al. Evaluation of the anti-tumor effect of gambogic acid loaded macrophage membranes nanoparticles combined with radiotherapy and anti-PD-1mAb in the colorectal cancer with liver metastasis model
Gómez-Escudero et al. Vascular Disruption Therapy as a New Strategy for Cancer Treatment
Pina et al. Transferrin Receptor 1-targeted polymersomes therapy for Colorectal Cancer
Chaudhary et al. Recent developments in the study of the microenvironment of cancer and drug delivery
Comito et al. Systemic and liver-directed therapies in metastatic uveal melanoma: State-of-the-art and novel perspectives
HK1206281B (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
WO2020227682A1 (en) Treating cancer
Huang et al. Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfusion Injury
US20220409581A1 (en) Methods and compositions for treatment of solid tumors using f16 isoindole small molecules

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206281

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: 18 floor, commercial building, Kowloon Bay, 8, Hong Kai Road, Hongkong, China

Patentee after: VISION GLOBAL HOLDINGS LTD.

Address before: Sheung Wan, Hongkong, China

Patentee before: VISION GLOBAL HOLDINGS LTD.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180824